Portfolio Category: Pharmaceuticals

ODE Pharma has developed an innovative and user-friendly biological medication that can potentially treat lung ailments and breathing difficulties, prevents deterioration of lung functions in people suffering from COVID-19, and enables them to recover quickly from the disease. The same pathological changes that compromise lung functions upon the COVID-19 infection also occur in other pulmonary diseases (e.g., Influenza, Asthma and CF) and thus can potentially be cured by our solution. ODE Pharma was born out of the collaboration between the Hebrew University of Jerusalem, Professor Shmuel Ben-Sasson (inventor and lead scientist) and Pollen Innovation Ltd, an Israeli-based investment firm focused on accelerating disruptive innovations and trends that enhance quality of life and contribute to a better and healthier world.

Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by pioneering the development of next generation immune oncology (IO) therapies.

HighRAD’s products are designed around its novel Region of Difference (ROD) generic platform and methodology for automatic, robust, and accurate lesion changes analysis in longitudinal volumetric scans, including CT and MRI scans.

Many drugs can trigger serious side effects due to their chemical structure. At BioNanoSim we redesign these medicines using our proprietary nano-encapsulation technology. We make them significantly better than the original form with improved potency and less risk.

Revolutionizing diabetes treatment. Betalin is currently carrying pre-clinical studies and in discussions with both the Human Tissue Association (UK) and Food Drug Association (US) to begin clinical trials. Betalin Therapeutics licensed the novel Engineered Micro Pancreas (EMP) technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.  

Our novel droplet technology provides enhanced bio-availability for both anterior and posterior segments of the eye. High solubility capacity transcends traditional limitations of size and polarity. the ability to achieve higher concentrations of known APIs enables treatment of severe cases, Improved safety and efficacy,reduced treatment burden, and targeted delivery capability enables topical treatment for posterior segment diseases like age related macular degeneration.

BacoCure is developing a novel bacterial product for local therapy (intravesicular) of patients with non-muscle invasive bladder cancer. BacoCure’s lead product is a novel mutated and inactivated uropathogenic bacteria that has demonstrated impressive anti-tumor effects via a novel and differentiated mechanism of action with a better safety profile compared to Bacillus Calmette-Guerin. The product is at an advanced preclinical development stage.

LipoCure’s founder, Professor Barenholz, the co-developer of Doxil®, has been investigating liposomal drug delivery systems for several decades. LipoCure’s unique platform technology is the result of many years of his intensive research efforts to bring the myriad sufferers more effective and safer therapies.

LipoCure’s proprietary platform implements a highly-efficient innovative approach which allows for the remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. Thus, this unique technology allows for an enhanced permeability and retention (EPR) effect, a significantly improved therapeutic effect and reduced side effects of several well-established drugs widely used for the treatment of rheumatoid arthritis, multiple sclerosis and cancer.

Established by Integra Holdings in 2014, NP-09 is at advanced preclinical development of an improved formulation of Propofol, based on technology developed by Prof. Nissim Garti from the Hebrew University. Current Propofol products are widely used for intravenous induction and maintenance of anesthesia, but are manufactured from animal and plant derived components with high risks of bacterial and fungal contamination leading to significant supply shortage, as well as significant manufacturer’s loss of revenues. NP09 is a novel bioequivalent Propofol formulation with proven superiority over Diprivan.

Vitalunga, an Israeli Biomedical startup led by Prof. Shmuel (Muli) Ben-Sasson and Prof. Einav Gross, The Hebrew University’s Faculty of Medicine, has developed a family of novel small-molecule drugs that precisely enhances autophagy and mitophagy. This platform technology opens the way for the treatment and prevention of multiple aging-associated diseases such as Alzheimer’s and Parkinson’s diseases, congestive heart failure, sarcopenia, AMD etc., utilizing a single oral agent.